what percentage of people get nausea from semaglutide exposure and nausea. Data show the proportion Less Nausea on Semaglutide: Simple

In our study, we examine: Trends in GLP-1 prevalence, adherence data, and potential obstacles to continued use Impacts on mortality among individuals taking these drugs Implications for assessing metabolic risk and the crucial role electronic health records (EHRs) will play Key results GLP-1s may drive 0.2%0.5% annual mortality improvement, realized over a 20-year period

19 Furthermore, Black adults are nearly twice as likely as their White counterparts to have diagnosed diabetes12.1% compared to 6.9% highlighting the urgent need for effective interventions in these communities

Comparing Zepbound and Mounjaro with Ozempic and Wegovy for the Treatment of Obesity Zepbound and Mounjaro, compared with Ozempic and Wegovy, represent advanced options for the treatment of obesity

How did your experience and skills translate to this new role